HUDDINGE, Sweden, May 16, 2019 /PRNewswire/ --Medivir AB (Nasdaq
Stockholm: MVIR) today informs that new data from the phase I
study of birinapant in combination with pembrolizumab (Keytruda®)
will be presented during the American Society of Clinical Oncology
annual meeting, which will take place 31 May – 04 June in
Chicago, USA.
The abstract 2506, Determination of the recommended phase ll
dose of birinapant in combination with pembrolizumab: Results from
the dose-escalation phase of BPT 201, will be presented at an
oral session 2nd June 2019 by Dr.
Russel J. Schilder, Thomas Jefferson University, Sidney Kimmel Cancer
Center, Philadelphia, USA.
Details of all presentations for the ASCO:s annual meeting are
available at the conference website:
http://asco-2019.org/.
About Birinapant
Birinapant is being developed to enhance responses, and extend
survival, of patients with solid tumors where existing treatments
do not provide sufficient survival benefit, or where patients no
longer have treatment options. Based on its unique design and
mechanism, birinapant has the potential to enhance patients'
responses in combination with other treatments. Medivir's initial
focus is on developing birinapant in combination with an
immuno-oncology agent.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the
unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. www.medivir.com.
For further information, please contact:
Uli
Hacksell
CEO, Medivir AB
Phone: +46 (0)73-125-0615.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/new-data-from-the-phase-i-study-of-birinapant-in-combination-with-keytruda--will-be-presented-at-the,c2815263
The following files are available for download:
|
https://mb.cision.com/Main/652/2815263/1046350.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/new-data-from-the-phase-i-study-of-birinapant-in-combination-with-keytruda-will-be-presented-at-the-asco-2019-300851466.html
SOURCE Medivir
